Compounds > 3-azidopyrimethamine
Page last updated: 2024-12-07

3-azidopyrimethamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3-azidopyrimethamine: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125330
MeSH IDM0157125

Synonyms (9)

Synonym
3-azidopyrimethamine
2,4-pyrimidinediamine, 5-(3-azido-4-chlorophenyl)-6-ethyl-
5-(2-azido-3-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
95458-40-5
2,4-diamino-5-(3-azido-4-chlorophenyl)-6-ethylpyrimidine
2,4-mzp
3-azidopyrimethamamine ethanesulfonate
5-(2-azido-3-chlorophenyl)-6-ethyl-2-imino-2,3-dihydropyrimidin-4-amine
DTXSID00914991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
anthralin
Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.		1.9710anthracenesantipsoriatic
pyrimethamine
Maloprim: contains above 2 cpds		3.0750aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		1.9710diazine;
pyrazines		Daphnia magna metabolite
metoprine
metoprine: histamine methyltransferase antagonist		1.9710
azides
Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.		3.0750pseudohalide anionmitochondrial respiratory-chain inhibitor
nsc 361456
pyrazine-2-diazohydroxide: structure in first source		1.9710
methotrexate
[no description available]		1.9710dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
ConditionIndicatedRelationship StrengthStudiesTrials
Metastase
[description not available]		01.9710
Sarcoma, Epithelioid
[description not available]		01.9710
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		01.9710
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		01.9710
Soft Tissue Neoplasms
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.		01.9710
Benign Neoplasms
[description not available]		01.9710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		01.9710
Experimental Neoplasms
[description not available]		02.3720